OTC:ESAIY

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment

Retrieved on: 
Friday, August 4, 2023
Carbon, Government Pension Investment Fund, FTSE Russell, Corporate governance, WIN, Index, Eisai, MSCI, Patient, ESG, Anti-corruption

The FTSE4Good Index Series is a global index series for socially responsible investment.

Key Points: 
  • The FTSE4Good Index Series is a global index series for socially responsible investment.
  • The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards.
  • As of the end of June 2023, 1,121 companies worldwide and 250 Japanese companies were included in the FTSE4Good Developed Index Series.
  • Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Retrieved on: 
Thursday, July 20, 2023
PK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GFAP, Glial fibrillary acidic protein, Clinical trial, SC, The New England Journal of Medicine, Pathology, PET, Brain, Biomarker, Clarity, Plasma, AAIC, Fluid mechanics, Amyloid, Astrocyte, Neurogranin, Lecanemab, AD, FDA, Conference, Food, Safety, Biogen, Medical imaging, Pharmaceutical industry, Alzheimer's disease, CSF

This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.

Key Points: 
  • This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.
  • The U.S. Food and Drug Administration (FDA) granted traditional approval for LEQEMBI for the treatment of Alzheimer's disease (AD) on July 6, 2023.
  • In an exposure/bioavailability and modeling study comparing intravenous (IV) and subcutaneous (SC) dosing of lecanemab, the bioavailability of SC dosing of lecanemab was shown to be approximately 50% of that of IV dosing.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Eisai to Present the Latest Alzheimer's Disease Pipeline and Research

Retrieved on: 
Wednesday, July 12, 2023
Washington University in St. Louis, Senior, Disease, Amyloid beta, Alzheimer's Disease Neuroimaging Initiative, Pharmacokinetics, Research, Biomarker, MCI, Lecanemab, Downstream, AAIC, Patient, Clinical research, AIC, Poster, AD, Conference, Safety, Pharmaceutical industry, Alzheimer's disease, Domination, Eisai

The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.

Key Points: 
  • The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.
  • Eisai will present data and research in eight oral and 19 poster presentations at the meeting.
  • Two of the AAIC oral presentations will be presented as posters at the Alzheimer's Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.
  • "At AAIC 2023 Eisai will present the latest data on lecanemab, an anti-Aβ protofibril antibody, that recently received traditional approval in the U.S. for patients with mild cognitive impairment (MCI) due to AD and mild AD.

Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Retrieved on: 
Friday, July 7, 2023
Amyloid-related imaging abnormalities, Insurance, Disease, CMS, Clinical trial, PCNS, The New England Journal of Medicine, Deficit spending, Research, Today, MCI, Neurotoxicity, Committee, Medicare, Clarity, ARIA, HIV disease progression rates, Patient, Immunoglobulin G, Co-promotion, Diagnosis, Lecanemab, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, ADCS, Conditional sentence, Pharmaceutical industry, Alzheimer's disease, Biogen, Eisai

Treatment with LEQEMBI should be initiated in patients with MCI or mild dementia stage of disease, (collectively referred to as early AD) the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with MCI or mild dementia stage of disease, (collectively referred to as early AD) the population in which treatment was initiated in clinical trials.
  • LEQEMBI treatment reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • Importantly, following FDA's traditional approval of LEQEMBI, CMS confirmed that broader coverage of LEQEMBI is now available and released more details on the registry, including the easy-to-use data submission process.
  • "Today, the FDA approved LEQEMBI under the traditional approval pathway, making LEQEMBI the first and only approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease.

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Retrieved on: 
Friday, June 30, 2023
Pressure, Maintenance, LifeArc, Partnership, University, Therapy, Life, Doctor of Philosophy, Speech, Public, Neurodegenerative disease, University of Edinburgh, Health, Ageing, Alzheimer's Research UK, Quality of life, ML, Research, Genomics, Biomarker, Mentorship, HDR, Disorder, Dementia, Alzheimer's disease, Digital technology, HIV disease progression rates, Patient, Orangi Pilot Project, Machine learning, Algorithm, Artificial intelligence, Drug discovery, Gates Ventures, Diagnosis, AI, Neurology, Disease, Pharmaceutical industry, Industrial design, Medical device, Nursing, Eisai

- NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.

Key Points: 
  • - NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
  • TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
  • NEURii will focus its initial efforts to develop data and digital solutions to complement approved treatment options for patients and solve issues related to the prediction, prevention, management, and treatment of dementia related disorders.
  • It is envisaged that NEURii partners will explore further opportunities to scale up the program developing digital health solutions worldwide.

Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City

Retrieved on: 
Thursday, June 22, 2023
Success, Policy, PFS, Dementia, Organization, Eisai, Nursing, Co-promotion, Self-assessment, Diagnosis, Patient, Social, Health, Disease, Residential care

TOKYO, June 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo.

Key Points: 
  • TOKYO, June 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo.
  • This project is designed to encourage approximately 12,300 Bunkyo City residents between the ages of 55 and 75, at a milestone of every 5 years, to have a brain health check using "NouKNOW".
  • The dementia examination project has been implemented since FY2021 as a priority policy of Bunkyo City, and Eisai has been providing "NouKNOW" and operational support for their public examinations.
  • In FY2023, Eisai will continue to raise awareness of brain health among residents and contribute to early detection and support of dementia.